Shots: The companies will partner to promote Lyumjev (insulin lispro-aabc injection, 100 & 200 units/mL) with Dexcom G6 CGM to aid HCPs in the US for the management of diabetes, including giving visibility to the benefits of a new mealtime insulin HCPs treating T1D & T2D will be able to assess their patient’s glucose levels […]Read More
Shots: Lannett has provided an update on the clinical advancement of its biosimilar Insulin glargine. Following FDA meeting, Lannett has received FDA’s positive feedback on the clinical and CMC advancement of its biosimilar insulin glargine The company anticipates the filing of 351(k) biosimilar application for its biosimilar insulin glargine candidate by the end of 2022 […]Read More
Shots: The P-III program involves assessing of Roxadustat vs PBO and epoetin alfa in 9,000+ NDD and DD & ID patients in multiple studies conducted by AstraZeneca, FibroGen and Astellas together globally respectively Results: The risk of MACE, MACE+ and all-cause mortality & Hb level (1.85 g/dL vs 0.13 g/dL) in NDD patients was comparable […]Read More
Shots: The program has two parts Growth Track, in which companies will receive €75 funding for co-creating solutions, as well as co-working space at Bayer’s Pharmaceuticals division headquarters in Berlin, Germany while Advance Track consist of project funds plus incremental milestone-based payments. Mentoring and Coaching is also part of G4ADigital program The partnership will support […]Read More
Shots: Black Belt to get $5.64M (€5M) upfront, equity investment of $2.26M (€2M), milestones and royalties on sales. CASI to get exclusive WW rights to develop and commercialize Black Belt’s anti-CD38 monoclonal antibody (Mab) TSK011010 program The equity investment of $2.26M will be in a newly built subsidiary of Black Belt focusing on novel immuno-oncology […]Read More
Shots: Xencor to receive an upfront, development, regulatory & commercialization milestones and royalties on sales of product. Astellas to get exclusive WW license to develop and commercialize bispecific mAb for cancer Xencor to utilize its XmAb technology for the development of bispecific Ab candidates against Astellas’ targets & will take care of initial characterization of […]Read More
Shots: Roche & Vaccibody collaborated to assess the combination of VB10.16 + Tecentriq in P-II, for 50 patients with advanced cervical cancer to evaluate its safety, tolerability, immunogenicity and efficacy The combination trial agreement is built upon the trial assessing VB10.16 monothx in patients with precancerous cervical lesion. Vaccibody plans for the onset of P-II […]Read More
Shots: Repare to receive $15M upfront, $160M milestones and royalties on sales of product from ONO. Repare to get exclusive development and commercialization rights for Repare’s Polθ Inhibitor Program in Japan, South Korea, Taiwan, Hong Kong, Macau and ASEAN countries Repare will retain development and commercialization rights (ex- ONO’s territory) for Polθ Inhibitor Program in […]Read More
Shots: Lilly to acquire Hydra, in all stock transaction with its all pre-clinical pain program of TRPA1 antagonists The focus of the acquisition is to develop treatments for chronic pain and understand TRP pathway in pain signaling, further initiate clinical trials Hydra’s Transient Receptor Potential (TRP) channel program consists of group of non-selective cation channels indicated for the treatment […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
